Rates of asthma exacerbations are not affected by beta2 -adrenergic receptor genotype in patients with persistent asthma Source: Eur Respir J 2005; 26: Suppl. 49, 708s Year: 2005
MUC1-CT mediates corticosteroid responses in COPD Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action Year: 2016
?2-adrenergic receptor polymorphisms, asthma and COPD: two large population-based studies Source: Eur Respir J 2012; 39: 558-566 Year: 2012
The effect of leukotrienes receptor antagonists on lung function, exercise tolerance and incidence of exacerbations in patients with stable, moderate COPD Source: Eur Respir J 2002; 20: Suppl. 38, 620s Year: 2002
Increased expression of ADRB2, CHRM3 and glucocorticoid alpha receptor genes in blood leukocytes of COPD patients Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action Year: 2016
Sputum cell mRNA transcripts demonstrate alteration of endothelin metabolism in severe asthma and COPD Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013
The role of response to bronchodilators in differential diagnosis of COPD and asthma Source: Eur Respir J 2003; 22: Suppl. 45, 424s Year: 2003
Glucocorticoid receptor-binding characteristics in severe asthma Source: Eur Respir J 2003; 21: 985-988 Year: 2003
Altered expression of glycosaminoglycans in the BAL of COPD patients with acute exacerbation Source: Annual Congress 2013 –Translational studies in chronic lung diseases: from bedside to bench Year: 2013
The role of IFN-γ in severe COPD patients with anamnestic viral-induced exacerbations before and after roflumilast treatment Source: International Congress 2016 – Translational studies in lung disease Year: 2016
L-arginine pathway metabolites can predict exacerbation independently from beta blocker treatment in patients with COPD: A follow-up study Source: International Congress 2016 – Systemic biomarkers Year: 2016
Increased interferon and decreased NRF2-PPARG signaling is associated with frequent exacerbations in COPD Source: International Congress 2015 – Promising novel findings in translational pulmonary research Year: 2015
Lung function, symptoms and prescription of inhaled steroids and long acting β2 agonists in patients managed by an integrated COPD team Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016
Salmeterol response is not affected by beta2 -adrenergic receptor genotype in patients with persistent asthma Source: Eur Respir J 2005; 26: Suppl. 49, 505s Year: 2005
The role of histone deacetylase 2 (HDAC2) and glucocorticoid receptor (GR) isoforms α, β in patients with asthma–COPD overlap syndrome (ACOS) Source: International Congress 2016 – Molecular targets in pulmonary disease Year: 2016
Interaction between the Arg16 homozygous genotype, inhaled corticosteroids and long acting beta agonists for asthma exacerbations in children? Leukotriene receptor antagonists to the rescue? Source: Annual Congress 2013 –Asthma and lung development: from genes to environment Year: 2013
Symptom profile of exacerbations in earlier and later COPD Source: Annual Congress 2013 –Asthma and COPD: diseases with different phenotypes Year: 2013
The role of bacteria in COPD exacerbations Source: International Congress 2014 – PG04 Update on COPD exacerbations Year: 2014
Effects of a single inhaled budesonide/formoterol dose on glucocorticoid receptor activity in sputum of COPD patients Source: International Congress 2016 – Novel insights into the treatment of COPD Year: 2016